C3-R: the present and the future

Article

You can leave the epithelium intact, say Dr Roberto Pinelli and Dr Tarek El Beltagi

Key Points

It was Professor Theo Seiler who first proposed applying the principally dental and orthopaedic concept of cross-linking to corneal collagen fibres as a treatment for ectasia; specifically, keratoconus (KC).

The procedure works because a combined use of riboflavin (vitamin B2) and ultraviolet-A (UV-A) irradiation induces a strengthening of corneal stroma, by creating, between the collagen fibres, new stromal bonds as a result of the UV-A radiation's effect on the unstable riboflavin molecule.

It was initially believed that the C3-R treatment required epithelial debridement to improve riboflavin penetration in the stroma, although more recently the treatment may be performed with the epithelium left intact. There remain differing opinions regarding the removal of the epithelium (or not): there are those who believe that, with the epithelium left on, the penetrating capability of riboflavin could be slower and the treatment less efficacious.

Can we prove it?

Related Videos
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Greg Kunst, CEO of Aurion Biotech
Trukera Medical rebranding ushers in new era of expansion into cornea market
Younger patients often require repeat corneal crosslinking, study finds
Utilising AAO cornea preferred practice patterns for corneal oedema, opacifications, ectasia and bacterial keratits
Investigating the effects of canaloplasty on corneal epithelium
Avoiding errors when converting to DMEK
EDOF lens tech is evolving to help more patients with intermediate vision
OC-01 (varenicline solution) investigated as possible treatment for dry eye symptoms, signs
© 2024 MJH Life Sciences

All rights reserved.